v3.26.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Mar. 01, 2024
Jan. 17, 2019
Allowance for doubtful accounts $ 0   $ 0   $ 0    
Advertising costs 18,298 $ 12,893 41,209 $ 16,133      
Goodwill impairment     0 0      
Intangible assets impairment 0 0 6,374 0      
Deferred Revenue 1,040   1,040   0    
Advertising costs       12,893      
Grant funding during the first year           $ 4,131,123 $ 2,842,430
Grant funding           11,029,977  
Grant funding during the second year           3,638,268 2,831,838
Grant funding during the third year           $ 3,260,586 3,453,367
Grant additional funding during the third year             $ 99,431
Grant receivables 102,613   102,613   52,026    
Deferred revenues related to grant     0   $ 0    
Grant income 679,477 154,270 1,042,074 568,249      
Research and development expenses $ 712,384 $ 296,860 $ 1,064,717 $ 458,779      
Ownership percentage     50.00%        
Royalty obligations description     The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued        
Description of Non-Controlling Interest     Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest        
Royalty obligations, net     $ 7,171,200        
Minimum [Member]              
Property plant and equipment estimated useful lives     5 years        
Maximum [Member]              
Property plant and equipment estimated useful lives     15 years